Treatment of obesity with diet/exercise versus pioglitazone has distinct effects on lipoprotein particle size

Atherosclerosis

Volumn 188, Issue 2, 2006, Pages 370-376

  Shadid, Samyah ^a,b   LaForge, Ralph ^c   Otvos, James D ^d   Jensen, Michael D ^a  

^a MAYO CLINIC   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d LIPOSCIENCE INC   (United States)

Author keywords

Cholesterol; Exercise; Insulin; Lipids; Nutrition; Weight loss

Indexed keywords

LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES CONTROL; DIET; DIET THERAPY; DRUG EFFECT; EXERCISE; FEMALE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; NUCLEAR MAGNETIC RESONANCE; OBESITY; PARTICLE SIZE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

ADULT; ANALYSIS OF VARIANCE; BLOOD CHEMICAL ANALYSIS; EXERCISE THERAPY; FEMALE; HUMANS; INSULIN RESISTANCE; LIPOPROTEINS; MALE; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; OBESITY; PARTICLE SIZE; THIAZOLIDINEDIONES; WEIGHT LOSS;

EID: 33748187085     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2005.10.038     Document Type: Article

References (23)

1. Lamarche B., Lemieux I., and Despres J.P. The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects. Diab Metab 25 (1999) 199-211
2. Sacks F.M., and Campos H. Low-density lipoprotein size and cardiovascular disease: a reappraisal. J Clin Endocrinol Metab 88 (2003) 4525-4532
3. Berneis K.K., and Krauss R.M. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 43 (2002) 1363-1379
4. Blackburn P., Lemieux I., Lamarche B., et al. Effect of type 2 diabetes on various electrophoretic characteristics of low-density lipoprotein particles in women. Diabetologia 47 (2004) 2114-2117
5. Wagner A.M., Jorba O., Rigla M., et al. Effect of improving glycemic control on low-density lipoprotein particle size in type 2 diabetes. Metabolism 52 (2003) 1576-1578
6. Abbasi F., Chu J.W., McLaughlin T., et al. Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus. Metabolism 53 (2004) 159-164
7. Winkler K., Konrad T., Fullert S., et al. Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. Diab Care 26 (2003) 2588-2594
8. Neuschwander-Tetri B.A. Evolving pathophysiologic concepts in nonalcoholic steatohepatitis. Curr Gastroenterol Rep 4 (2002) 31-36
9. Promrat K., Lutchman G., Kleiner D.E., et al. Pilot study of pioglitazone in nonalcoholic steatohepatitis. Gastroenterology 124 (2003) A-708 [Abstract]
10. Sarafidis P.A., Lasaridis A.N., Nilsson P.M., et al. Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase. J Hypertens 22 (2004) 1769-1777
11. Goldberg R.B., Kendall D.M., Deeg M.A., et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabtes and dyslipidemia. Diab Care 28 (2005) 1547-1554
12. Shadid S., and Jensen M.D. Effects of pioglitazne vs. diet and exercise on metabolic health and fat distribution in upper body obesity. Diab Care 26 (2003) 3148-3152
13. Bergman R.N., Ider Y.Z., Bowden C.R., and Cobelli C. Quantitative estimation of insulin sensitivity. Am J Physiol 236 (1979) E667-E677
14. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
15. Otvos J.D. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin Lab 48 (2002) 171-180
16. Festa A., Williams K., Hanley A.J., et al. Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study. Circulation 111 (2005) 3465-3472
17. Harder H., Dinesen B., and Astrup A. The effect of a rapid weight loss on lipid profile and glycemic control in obese type 2 diabetic patients. Int J Obes 28 (2004) 180-182
18. Kraus W.E., Houmard J.A., Duscha B.D., et al. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med 347 (2002) 1492
19. Carr M.C., Hokanson J.E., Zambon A., et al. The contribution of intraabdominal fat to gender differences in hepatic lipase activity and low/high density lipoprotein heterogeneity. J Clin Endocrinol Metab 86 (2001) 2831-2837
20. Bogacka I., Xie H., Bray G.A., and Smith S.R. The effect of pioglitzaone on peroxisome proliferator-activated receptor-gamma target genes related to lipid storage in vivo. Diab Care 27 (2004) 1660-1667
21. Lewis G.F., Murdoch S., Uffelman K., et al. Hepatic lipase mRNA, protein, and plasma enzyme activity is increased in the insulin-resistant, fructose-fed Syrian golden hamster and is partially normalized by the insulin sensitizer rosiglitazone. Diabetes 53 (2004) 2893-2900
22. Wilmsen H.M., Ciaraldi T.P., Carter L., et al. Thiazolidinediones upregulate impaired fatty acid uptake in skeletal muscle of type 2 diabetic subjects. Am J Physiol Endocrinol Metab 285 (2003) E354-E362
23. Cromwell W.C., and Otvos J.D. Low-density lipoprotein particle number and risk for cardiovascular disease. Curr Atheroscler Rep 6 (2004) 381-387